By Staff Reports
(DGIwire) — For many caffeine lovers, that morning cup of coffee is more than a mere drink—it’s a ritual. In fact, it might even transcend ritual and verge on medicinal. According to a recent article in Tech Times, caffeine intake can actually reduce the risk of various diseases and improve overall health. The article cited a study from the Harvard School of Public Health in which researchers found that people who drank coffee regularly saw a small drop in their risk of developing Type 2 diabetes. Dr. Frank Hu, professor of nutrition and epidemiology at Harvard, reported observing the biggest reduction in Type 2 diabetes risk in people who drank three to five cups of coffee a day.
For those who already have Type 2 diabetes, Boston Therapeutics, a pharmaceutical company based in Manchester, NH, is studying a product that might someday help. Called BTI-320, it’s a non-systemic, chewable, complex carbohydrate-based compound, specifically designed to reduce the spikes in blood sugar that are common after meals. Intended to be taken before meals, it works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars. This process reduces the amount of glucose available to be absorbed into the bloodstream.
Boston Therapeutics recently announced that the U.S. Food and Drug Administration (“FDA”) has accepted the company’s Investigational New Drug Application (“IND”) for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial.
“Earlier this year, we completed a U.S.-based Phase IIb study of BTI-320 in patients with Type 2 diabetes and reported positive topline results. The results of our studies to date provided us with information on different patient populations and doses that have allowed us to design a protocol for this trial using mean change in HbA1c as the primary endpoint, which is the standard for measuring efficacy in currently available diabetes therapies,” says David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics.